<DOC>
	<DOCNO>NCT01068730</DOCNO>
	<brief_summary>To demonstrate bioequivalence 500 mg 1000 mg Glucophage tablet manufacture BMS relative respective strength 500 mg 1000 mg Diabex tablet market Australia Alphapharm feed state</brief_summary>
	<brief_title>Bioequivalence Study 500 mg 1000 mg Glucophage ( Metformin ) Tablets Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Men woman age 18 55 inclusive Healthy subject determine clinically significant deviation normal medical history , physical examination , electrocardiogram ( ECGs ) , clinical laboratory determination Body Mass Index ( BMI ) 18 32 kg/m² , inclusive . BMI = weight ( kg ) / [ height ( ) ] ² Any significant acute chronic medical illness Current recent ( within 3 month ) gastrointestinal disease Any major surgery within 4 week study drug administration History allergy intolerance metformin similar acting agent Prior exposure metformin within 3 month study drug administration Estimated creatinine clearance ( Clcr ) &lt; 80ml/min use Cockcroft Gault formula</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>